OncoMatch/Clinical Trials/NCT06385418
Fluorouracil Treatment Via Colon for Colorectal Cancer
Is NCT06385418 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Colonic local administration of fluorouracil with enhanced adhesion for colorectal cancer.
Treatment: Colonic local administration of fluorouracil with enhanced adhesion — Fluorouracil (5-FU) is a commonly used drug for colorectal cancer (CRC). Thermosensitive hydrogel presents a promising carrier for 5-FU to address challenges encountered with traditional administration methods. We propose an integrated approach utilizing colonic transendoscopic enteral tubing to cover the entire colon flexibly, coupled with a thermo-sensitive gel to enhance the adhesion of 5-FU. This clinical trial aims to assess the feasibility, safety, and efficacy of this approach for treating CRC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Colorectal Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5 × 10^9/L, platelets ≥100 × 10^9/L, hemoglobin ≥90 g/L
Kidney function
Creatinine <120 μmol/L, or MDRD eGFR >60 mL/min
Liver function
Total bilirubin ≤1.5x ULN (≤3x ULN with biliary drainage); ALT and AST ≤5x ULN; for patients with liver metastases, serum total bilirubin ≤3x ULN
Cardiac function
LVEF ≥50% by Doppler echocardiography
Adequate organ function meeting the following criteria: (1) Absolute neutrophil count ≥1.5 × 10^9/L, platelets ≥100 × 10^9/L, hemoglobin ≥90 g/L; (2) Total bilirubin ≤1.5 times the upper limit of normal (patients with biliary drainage via retrograde techniques included); ALT and AST ≤5 times the upper limit of normal, and for patients with liver metastases, serum total bilirubin less than or equal to 3 times the upper limit of the normal reference range; (3) Creatinine <120 μmol/L, or MDRD estimated glomerular filtration rate >60 mL/min; (4) Doppler echocardiography assessment: Left ventricular ejection fraction (LVEF) ≥50%;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06385418 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages